Search Medical Condition
Please enter condition
Please choose location from dropdown

Parkville, Melbourne, Australia Clinical Trials

A listing of Parkville, Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (192) clinical trials

Evaluation of the Duration of Therapy for Thrombosis in Children

Children (birth to 21 years of age, inclusive) with first-episode venous thrombosis in association with a reversible clinical trigger (key exclusions: history of cancer; severe thrombophilia state disclosed) are enrolled and prescribed anticoagulation according to the clinical standard of care and American College of Physicians (Chest journal) 2012 recommendations. At ...

Phase

0.0 miles

Learn More »

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care ...

Phase N/A

0.0 miles

Learn More »

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.

Phase

0.0 miles

Learn More »

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects 1 Month to <4 Years With Partial-onset Seizures

The trial consists of a 7-day Baseline Period, a 20-day Titration Period, a 7-day Maintenance Period, and a 12-day Transition Period for subjects who complete the study and choose to enter the extension study. Subjects who will not enter the extension study will continue after the Maintenance Period with a ...

Phase

0.0 miles

Learn More »

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures. Initially, subjects taking phenytoin or phenobarbital will be enrolled followed by additional subjects taking anti-epileptic drugs other than phenytoin and phenobarbital to further investigate long-term safety.

Phase

0.0 miles

Learn More »

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy. A total of 600 patients will be randomly assigned to 2 treatment arms in a 1:1 ratio (300 in each arm) to reach at ...

Phase

0.0 miles

Learn More »

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Phase

0.0 miles

Learn More »

Evaluation of a Patient-Reported Symptom Index for NMIBC

The overarching aim of this research is to develop and evaluate a patient-reported Symptom Index (SI) for individuals with NMIBC (the NMIBC-SI) that is acceptable to patients, reliable, valid and responsive, and fit for purpose in clinical trials and clinical practice. Specific clinical aims: Assess and compare key Patient-Reported Outcomes ...

Phase N/A

0.23 miles

Learn More »

Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients

This study is designed to investigate in a prospective, randomised fashion whether a single intravenous dose of rituximab (375 mg/m2) given two weeks prior to transplant, in addition to standard therapy, will allow sensitised renal transplant subjects to achieve a negative CDC crossmatch and thereby proceed to live donor transplantation. ...

Phase

0.23 miles

Learn More »